The Division of Neuro-Oncology seeks adult men and women ages 18 and older with primary central nervous system lymphoma (PCNSL) for a research study. The purpose of this study is to evaluate the effect of an investigational drug called obinutuzumab when given to patients with PCNSL who have attained a complete response to first-line treatment with methotrexate-based therapy with or without brain radiotherapy. Patients who participate in this study will either receive study treatment with obinutuzumab once every 2 months for 2 years or will enter the observation group (standard of care) with no active treatment.
You may be eligible for this study if:
You have been diagnosed with primary central nervous system lymphoma (PCNSL). You have completed first-line treatment for PCNSL with a methotrexate-based chemotherapy regimen and achieved a complete response. You are within 75 days of completing your first-line treatment regimen for PCNSL.
Study participation may involve receiving an experimental intravenous (IV) medicine (if randomly assigned to treatment group), neurocognitive testing, and questionnaires. Visit schedules and length of visits will vary based upon study arm assignment.
Study medication and study-related assessments will be provided free of charge.